Elixir Medical Corporation

NovolimusMetabolite Drug

SHARE

Novolimus is a metabolite of the drug Sirolimus, a novel mTOR inhibitor macrolytic lactone with anti-proliferative and anti-inflammatory properties developed by Elixir Medical. The macrocyclic lactone drugs represent the most widely utilized drug family for drug-eluting stent applications and have an established safety and efficacy profile.

Most popular related searches

Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX, DESyne®, DESyne® BD and the fully resorbable DESolve® and DESolve® Cx scaffolds have resulted in excellent clinical outcomes and sustained safety and effectiveness.